Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 629 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 21
States / cities: Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more

Conditions: Cerebral Arterial Diseases
Interventions: Indomethacin 25 MG/50 MG, Placebo - Lactose; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dyspepsia, Helicobacter Pylori Infection
Interventions: RHB-105, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Anaheim, California • Chino, California • Jupiter, Florida + 8 more

Conditions: Myelodysplastic Syndromes, MDS, RAEB, Chronic Myelomonocytic Leukemia
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 41
States / cities: Scottsdale, Arizona • La Jolla, California • Stanford, California + 35 more

Conditions: Lateral Canthal Lines
Interventions: botulinum toxin, Placebo; Biological
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Manhattan Beach, California • San Diego, California • Solana Beach, California + 5 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID ΔM2-2 1030s vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
Interventions: nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Pituitary Disorders, Adult Growth Hormone Deficiency
Interventions: growth hormone; Drug
Lead sponsor: LG Life Sciences; Industry
Eligibility: 23 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: COVID-19
Interventions: Ampion, Saline; Biological · Other
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more

Conditions: Influenza, Human
Interventions: F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH, F2H23H/DL001Z, FDQ23A-NH (Flu D-QIV), GSK5800544A, Flu D-TIV, F2H23A/DL001Z-NH, F2H23G/DL001Z, Fluzone HD Quadrivalent, Fluzone HD; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 845 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 18
States / cities: Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Complex Regional Pain Syndrome, Type I
Interventions: lenalidomide, Placebo; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Peoria, Arizona • La Jolla, California • Loma Linda, California + 23 more

Conditions: Social Anxiety Disorder
Interventions: Quetiapine; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: GW679769; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Carvedilol, Placebo; Drug
Lead sponsor: Columbia Northwest Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: San Diego, California • Lake Charles, Louisiana • Bellevue, Washington

Conditions: Early Parkinson Disease
Interventions: K0706, placebo; Drug · Other
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 50 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more

Conditions: Chronic Pain, Soft Tissue Injuries, Wound Heal, Blood Flow
Interventions: Laser Doppler, Radiofrequency Heating System, Thermal Imaging, Healthcare Questionnaire & Measurement; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oregovomab; Biological
Lead sponsor: AltaRex; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 15
States / cities: Newport Beach, California • Fort Myers, Florida • Orlando, Florida + 11 more

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more

Conditions: Mild to Moderate Traumatic Brain Injury
Interventions: PoNS Treatment; Device
Lead sponsor: Helius Medical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Memphis, Tennessee

Conditions: Healthy Volunteers
Interventions: AEF0117, Placebo; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Generalized Myasthenia Gravis
Interventions: zilucoplan (RA101495), Placebo; Drug
Lead sponsor: Ra Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 26
States / cities: Mobile, Alabama • Carlsbad, California • Los Angeles, California + 22 more

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

Human Cerebral Blood Flow Regulation

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

Treatment of Moderate to Severe Lateral Canthal Lines

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Treatment of Adults With Growth Hormone Deficiency

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

Study Of GW679769 In Major Depressive Disorder

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Radiofrequency Hyperthermia Safety Study

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

PoNS Clinical Experience Program (TBI)

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis